CVOTs evaluating GLP-1 receptor agonist’s (GLP-1 RA) effects on cardiovascular outcomes have consistently shown a reduction in MACE rates, primarily in rates of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death. The gene discussed is GLP1R; the disease is stroke disorder.